190 related articles for article (PubMed ID: 35119498)
1. Comparison of characteristics and tumor targeting properties of extracellular vesicles derived from primary NK cells or NK-cell lines stimulated with IL-15 or IL-12/15/18.
Aarsund M; Segers FM; Wu Y; Inngjerdingen M
Cancer Immunol Immunother; 2022 Sep; 71(9):2227-2238. PubMed ID: 35119498
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming.
Zhu L; Kalimuthu S; Oh JM; Gangadaran P; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
Biomaterials; 2019 Jan; 190-191():38-50. PubMed ID: 30391801
[TBL] [Abstract][Full Text] [Related]
3. NKG2A and circulating extracellular vesicles are key regulators of natural killer cell activity in prostate cancer after prostatectomy.
Lu YC; Ho CH; Hong JH; Kuo MC; Liao YA; Jaw FS; Cheng JC; Huang CY; Chang KP; Chen CH; Lin JA; Hsiao A; Kung HN
Mol Oncol; 2023 Aug; 17(8):1613-1627. PubMed ID: 36931723
[TBL] [Abstract][Full Text] [Related]
4. Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma.
Zhuang L; Fulton RJ; Rettman P; Sayan AE; Coad J; Al-Shamkhani A; Khakoo SI
Hepatol Int; 2019 Jan; 13(1):75-83. PubMed ID: 30467624
[TBL] [Abstract][Full Text] [Related]
5. Cytokine-enhanced cytolytic activity of exosomes from NK Cells.
Enomoto Y; Li P; Jenkins LM; Anastasakis D; Lyons GC; Hafner M; Leonard WJ
Cancer Gene Ther; 2022 Jun; 29(6):734-749. PubMed ID: 34316033
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-18 synergism with interleukin-2 in cytotoxicity and NKG2D expression of human natural killer cells.
Qi YY; Lu C; Ju Y; Wang ZE; Li YT; Shen YJ; Lu ZM
Asian Pac J Cancer Prev; 2014; 15(18):7857-61. PubMed ID: 25292077
[TBL] [Abstract][Full Text] [Related]
7. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12.
Girart MV; Fuertes MB; Domaica CI; Rossi LE; Zwirner NW
J Immunol; 2007 Sep; 179(6):3472-9. PubMed ID: 17804388
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of interleukin-12 and interleukin-15 on expansion of NK cell receptor-expressing CD8+ T cells.
Sugita J; Tanaka J; Yasumoto A; Shiratori S; Wakasa K; Kikuchi M; Shigematsu A; Kondo T; Asaka M; Imamura M
Ann Hematol; 2010 Feb; 89(2):115-20. PubMed ID: 19578849
[TBL] [Abstract][Full Text] [Related]
9. NKG2D functions as an activating receptor on natural killer cells in the common marmoset (Callithrix jacchus).
Watanabe M; Kudo Y; Kawano M; Nakayama M; Nakamura K; Kameda M; Ebara M; Sato T; Nakamura M; Omine K; Kametani Y; Suzuki R; Ogasawara K
Int Immunol; 2014 Nov; 26(11):597-606. PubMed ID: 24860119
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
11. Isolation of a cytolytic subpopulation of extracellular vesicles derived from NK cells containing NKG7 and cytolytic proteins.
Aarsund M; Nyman TA; Stensland ME; Wu Y; Inngjerdingen M
Front Immunol; 2022; 13():977353. PubMed ID: 36189227
[TBL] [Abstract][Full Text] [Related]
12. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
13. Natural-Killer-Derived Extracellular Vesicles: Immune Sensors and Interactors.
Federici C; Shahaj E; Cecchetti S; Camerini S; Casella M; Iessi E; Camisaschi C; Paolino G; Calvieri S; Ferro S; Cova A; Squarcina P; Bertuccini L; Iosi F; Huber V; Lugini L
Front Immunol; 2020; 11():262. PubMed ID: 32231660
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.
Zhang C; Zhang J; Niu J; Zhou Z; Zhang J; Tian Z
Hum Immunol; 2008 Aug; 69(8):490-500. PubMed ID: 18619507
[TBL] [Abstract][Full Text] [Related]
15. Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells.
Chen Y; Chen B; Yang T; Xiao W; Qian L; Ding Y; Ji M; Ge X; Gong W
Cell Mol Immunol; 2017 Mar; 14(3):293-307. PubMed ID: 26364916
[TBL] [Abstract][Full Text] [Related]
16. Effect of cytokines on NK cell activity and activating receptor expression in high-risk cutaneous melanoma patients.
Martinović KM; Milićević M; Larsen AK; Džodić R; Jurišić V; Konjević G; Vuletić A
Eur Cytokine Netw; 2019 Dec; 30(4):160-167. PubMed ID: 32096478
[TBL] [Abstract][Full Text] [Related]
17. NKG2D Signaling between Human NK Cells Enhances TACE-Mediated TNF-α Release.
Sharma N; Trinidad CV; Trembath AP; Markiewicz MA
J Immunol; 2017 Oct; 199(8):2865-2872. PubMed ID: 28893955
[TBL] [Abstract][Full Text] [Related]
18. Influence of in vitro IL-2 or IL-15 alone or in combination with Hsp-70-derived 14-mer peptide (TKD) on the expression of NK cell activatory and inhibitory receptors.
Hromadnikova I; Pirkova P; Sedlackova L
Mediators Inflamm; 2013; 2013():405295. PubMed ID: 23476104
[TBL] [Abstract][Full Text] [Related]
19. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.
Basher F; Jeng EK; Wong H; Wu J
Oncotarget; 2016 Jan; 7(1):814-30. PubMed ID: 26625316
[TBL] [Abstract][Full Text] [Related]
20. MICA/IL-12: A novel bifunctional protein for killer cell activation.
Tietje A; Yang X; Yu X; Wei Y
Oncol Rep; 2017 Mar; 37(3):1889-1895. PubMed ID: 28098874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]